Partial-thickness Burn — Efficacy and Safety of Aluminaid Versus Hydrogel Wound Dressings
Citation(s)
Cancio LC, Lundy JB, Sheridan RL Evolving changes in the management of burns and environmental injuries. Surg Clin North Am. 2012 Aug;92(4):959-86, ix. doi: 10.1016/j.suc.2012.06.002. Review.
Grippaudo FR, Carini L, Baldini R Procutase versus 1% silver sulphadiazine in the treatment of minor burns. Burns. 2010 Sep;36(6):871-5. doi: 10.1016/j.burns.2009.10.021. Epub 2010 Jan 15.
Hettiaratchy S, Dziewulski P ABC of burns: pathophysiology and types of burns. BMJ. 2004 Jun 12;328(7453):1427-9. Review. Erratum in: BMJ. 2004 Jul 17;329(7458):148.
Selig HF, Lumenta DB, Giretzlehner M, Jeschke MG, Upton D, Kamolz LP The properties of an "ideal" burn wound dressing--what do we need in daily clinical practice? Results of a worldwide online survey among burn care specialists. Burns. 2012 Nov;38(7):960-6. doi: 10.1016/j.burns.2012.04.007. Epub 2012 May 8.
Serrano C, Boloix-Tortosa R, Gómez-Cía T, Acha B Features identification for automatic burn classification. Burns. 2015 Dec;41(8):1883-1890. doi: 10.1016/j.burns.2015.05.011. Epub 2015 Jul 15.
Wasiak J, Cleland H, Campbell F, Spinks A Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD002106. doi: 10.1002/14651858.CD002106.pub4. Review.
Efficacy and Safety of Aluminaid Versus Hydrogel Wound Dressings in the Treatment of Partial Thickness Burns
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
